Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @1stOncology
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @1stOncology
-
Prikvačeni tweet
1stOncology supports the aims of
#WorldCancerDay
2020 and its mission to save millions of preventable deaths each year by raising awareness and education about cancer. Learn more at: https://www.uicc.org/events/world-cancer-day-2020 …pic.twitter.com/VBgIU5mQzX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
#CytoSorb Used Successfully to Help Treat Grade 4#CytokineReleaseSyndrome Following#CARTcell#Immunotherapy in First Published Case Report$CTSO https://www.1stoncology.com/blog/cytosorb-used-successfully-to-help-treat-grade-4-cytokine-release-syndrome-following-car-t-cell-immunotherapy-in-first-published-case-report1234553902 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
#BloodTest Accurately Identifies#HPVRelated#HeadandNeckCancer Recurrence; Prospective Clinical Study Published in Journal of Clinical#Oncology https://www.1stoncology.com/blog/blood-test-accurately-identifies-hpv-related-headneck-cancer-recurrence-prospective-clinical-study-published-in-journal-of-clinical-oncology1234553899 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
#Moleculin to Seek Accelerated#FDA Approval and Plans for Pivotal Phase 2#AML Trial$MBRX https://www.1stoncology.com/blog/moleculin-to-seek-accelerated-fda-approvalplans-for-pivotal-phase-2-aml-trial1234553896 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#AIMImmunoTech Announces Completion of Third-Party Clinical Trial Using#Ampligen in Combination with Other Therapies as#Adjuvant Treatment of Peritoneal Surface Malignancies$AIM https://www.1stoncology.com/blog/aim-immunotech-announces-completion-of-third-party-clinical-trial-using-ampligen-in-combination-with-other-therapies-as-adjuvant-treatment-of-peritoneal-surface-malignancies1234553895 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Trovagene to Present New Clinical Data for#Onvansertib in#Metastatic#CastrationResistant#ProstateCancer at#ASCO Genitourinary Cancers Symposium$TROV https://www.1stoncology.com/blog/trovagene-to-present-new-clinical-data-for-onvansertib-in-metastatic-castration-resistant-prostate-cancer-at-asco-genitourinary-cancers-symposium1234553892 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#PhioPharmaceuticals Announces $1.74 Million Registered#DirectOffering Priced At-the-Market$PHIO https://www.1stoncology.com/blog/phio-pharmaceuticals-announces-1-74-million-registered-direct-offering-priced-at-the-market1234553891 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
#Genprex to Focus Its Clinical Efforts on#Oncoprex™ in#CombinationTherapy with#Osimertinib for#NonSmallCellLungCancer (#NSCLC)$GNPX https://www.1stoncology.com/blog/genprex-to-focus-its-clinical-efforts-on-oncoprex%E2%84%A2-in-combination-therapy-with-osimertinib-for-non-small-cell-lung-cancer-nsclc1234553888 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#MaaTPharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of#MicrobiomeBiotherapeutics https://www.1stoncology.com/blog/maat-pharma-announces-18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics1234553886 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#CD19#CARNKCellTherapy achieves 73% response rate in patients with#Leukemia and#Lymphoma https://www.1stoncology.com/blog/cd19-car-nk-cell-therapy-achieves-73-response-rate-in-patients-with-leukemialymphoma1234553885 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (“NewCo”)$MRK https://www.1stoncology.com/blog/merck-to-focus-on-key-growth-pillars-through-spinoff-of-women-s-health-trusted-legacy-brandsbiosimilars-products-into-new-company-newco1234553878 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Bellicum Announces Reverse Stock Split$BLCM https://www.1stoncology.com/blog/bellicum-announces-reverse-stock-split1234553875 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
#bluebirdbio Announces Upcoming Investor Events$BLUE https://www.1stoncology.com/blog/bluebird-bio-announces-upcoming-investor-events1234553868 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#SIRIONBiotech Licenses#Adenovirus Technology to Danish Startup,#InProTher for its Novel#Immunotherapy Design Targeting#EndogenousRetrovirus (#ERV) https://www.1stoncology.com/blog/sirion-biotech-licenses-adenovirus-technology-to-danish-startup-inprother-for-its-novel-immunotherapy-design-targeting-endogenous-retrovirus-erv1234553846 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#JuviséPharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less Than One Month https://www.1stoncology.com/blog/juvis%C3%A9-pharmaceuticals-successfully-syndicated-its-eur-213-million-financing-in-less-than-one-month1234553843 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.